The raised revenue guidance is a clear positive, but the volixibat delay and GAAP EPS miss temper the outlook. Traders should watch for upcoming brelovitug Phase 3 data (Q3/Q4 2026) and the zilurgisertib PDUFA date (Sept 26, 2026) as key catalysts. The convertible note issuance strengthens the balance sheet but adds dilution risk.
Price Chart
Executive Summary
Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2M, a 38% YoY increase, and raised full-year guidance to $680M-$700M. However, GAAP EPS was -$1.06, a significant miss vs the -$0.75 consensus, driven by heavy R&D and SG&A spending. The volixibat NDA submission was delayed to H1 2027 after the FDA recommended a Phase 3 study, a key pipeline setback. The strong commercial performance and raised guidance are offset by the earnings miss and the volixibat delay, resulting in a mixed outlook.
Key Financial Metrics
Key Facts
- Q2 2026 net product sales of $176.2M, up 38% YoY from $127.8M.
- Full-year 2026 net product sales guidance raised to $680M-$700M from $660M-$680M.
- GAAP net loss per share of -$1.06 vs consensus of -$0.75 (a miss).
- Volixibat NDA submission for PSC delayed to H1 2027 after FDA recommended a Phase 3 study.
- Issued $690M of 0.00% convertible senior notes due 2032 and settled $237.2M of 4.00% notes.
- Cash and investments of $561.3M as of June 30, 2026.
Financial Impact
Revenue beat by $9.8M (+5.9%) vs $166.4M consensus; EPS missed by -$0.31 (-41.3%) vs -$0.75 consensus.
Risk Factors
- Volixibat NDA submission delay to H1 2027 after FDA requested a Phase 3 study.
- GAAP EPS miss of -$1.06 vs consensus -$0.75, driven by high operating expenses.
- Potential dilution from the $690M convertible note issuance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759425-26-000044 |
| Document: mirm-20260805.htm | 0001759425-26-000044 |
| Document: 0001759425-26-000044-index-headers.html | 0001759425-26-000044 |
| Document: 0001759425-26-000044-index.html | 0001759425-26-000044 |
| Document: 0001759425-26-000044.txt | 0001759425-26-000044 |
| 8-K Data (Synthetic) | 0001759425-26-000044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $102.24 $98.82 | ▼ −3.35% | ▼ −1.39% | $82.58 (−19.23%) |
Aug 12, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▲ +1.66% | ▲ +3.55% | $82.58 (−16.56%) |
Aug 11, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▼ −1.66% | ▼ −3.55% | $82.58 (+16.56%) |
Aug 10, 2026 7w ago | 144 | $98.23 $98.30 | ▲ +0.07% | ▲ +1.13% | $82.58 (−15.93%) |
Aug 5, 2026 8w ago | 8-K | $94.12 $100.63 | ▲ +6.92% | ▲ +6.32% | $82.58 (−12.26%) |
Jul 8, 2026 12w ago | Insider Cluster | $128.57 $105.79 | ▼ −17.72% | ▼ −20.99% | $82.58 (−35.77%) |
Jun 11, 2026 16w ago | Institutional Cluster | $99.54 $127.70 | ▲ +28.29% | ▲ +26.40% | $82.58 (−17.04%) |
Jun 10, 2026 16w ago | Insider Cluster | $94.00 $127.70 | ▲ +35.85% | ▲ +32.23% | $82.58 (−12.15%) |
Jun 2, 2026 17w ago | Insider Cluster | $91.84 $125.59 | ▲ +36.76% | ▲ +37.76% | $82.58 (−10.08%) |
Jun 1, 2026 17w ago | 144 | $92.17 $120.46 | ▲ +30.69% | ▲ +32.26% | $82.58 (−10.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access